Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study

详细信息    查看全文

• 作者：Ekin Oktay Oguz ; Orhan Kucuksahin ; Murat Turgay…
• 关键词：Connective tissue disease ; Connective tissue disease ; related interstitial lung disease ; Interstitial lung disease ; Krebs von den Lungen ; 6
• 刊名：Clinical Rheumatology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：35
• 期：3
• 页码：663-666
• 全文大小：227 KB
• 参考文献：1.Olson AL, Brown KK, Fischer A (2012) Connective tissue disease-associated lung disease. Immunol Allergy Clin North Am 32:513–536CrossRef PubMed
  2.Fischer A, Chartrand S (2015) Assessment and management of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 22(32):2–21
  3.Kohno N (1999) (1999) Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 46:151–158PubMed
  4.Hu Y, Wang LS, Jin YP, et al. (2015) Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients. Clin Respir J. doi: 10.1111/crj.12341. [Epub ahead of print]
  5.Ishikawa N, Hattori N, Yokoyama A et al (2012) Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Inverstig 50:3–13
  6.Bonella F, Costabel U (2014) Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 35:181–200CrossRef PubMed
  7.Kobayashi J, Kitamura S (1995) KL-6: a serum marker for interstitial pneumonia. Chest 108:311–315CrossRef PubMed
  8.Kobayashi J, Kitamura S (1996) Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 109:1276–82CrossRef PubMed
  9.Yanaba K, Hasegawa M, Hamaguchi Y et al (2003) Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 21:429–436PubMed
  10.Doishita S, Inokuma S, Asashima H et al (2011) Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases. Intern Med 50:2889–2892CrossRef PubMed
  11.Ohnishi H, Yokoyama A, Kondo K et al (2002) Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165:378–381CrossRef PubMed
  12.Yamane K, Ihn H, Kubo M et al (2000) Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 27:930–934PubMed
  13.Bonella F, Volpe A, Caramaschi P et al (2011) Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 28:27–33PubMed
  14.Ohshimo S, Yokoyama A, Hattori N et al (2005) KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun 338:1845–1852CrossRef PubMed
  15.Ishikawa N, Mazur W, Toljamo T et al (2011) Ageing and long term smoking affects KL-6 levels in the lung, induced sputum and plasma. BMC Pulm Med 11:22CrossRef PubMed PubMedCentral
  16.Ashida T, Higashishiba M, Sumimoto Y et al (2001) Serum KL-6 levels in patients with pulmonary complications after allogeneic bone marrow transplantation. Int J Hematol 74:464–468CrossRef PubMed
  
• 作者单位：Ekin Oktay Oguz (1)
  Orhan Kucuksahin (2)
  Murat Turgay (2)
  Mustafa Turgut Yildizgoren (3)
  Askin Ates (2)
  Nalan Demir (4)
  Ozlem Ozdemir Kumbasar (4)
  Gulay Kinikli (2)
  Nursen Duzgun (2)
  
  1. Department of Internal Medicine, Ankara University Medical School, Ankara, Turkey
  2. Department of Rheumatology, Ankara University Medical School, Ankara, Turkey
  3. Department of Physical Medicine and Rehabilitation, Mustafa Kemal University Medical School, Hatay, Turkey
  4. Department of Chest Medicine, Ankara University Medical School, Ankara, Turkey
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  
• 出版者：Springer London
• ISSN：1434-9949

文摘

It was aimed to evaluate KL-6 glycoprotein levels to determine if it may be a diagnostic marker for the connective tissue diseases (CTDs) predicting CTD-related interstitial lung diseases (ILDs) (CTD-ILD) development and to examine if there was a difference between patients and healthy controls. The study included 113 patients with CTD (45 CTD without lung involvement, 68 CTD-ILD) and 45 healthy control subjects. KL-6 glycoprotein levels were analyzed with ELISA in patients and the control group. The relationship between KL-6 glycoprotein levels and CTD-ILD was assessed. In the comparison of all the groups in the study, significantly higher levels of KL-6 were determined in the CTD-ILD group than in either the CTD without pulmonary involvement group or the healthy control group (p < 0.008 and p < 0.001, respectively). There was no statistically significant difference between the KL-6 levels in the healthy control group and the CTD without pulmonary involvement group (p = 0.289). The KL-6 levels did not differ significantly according to the connective tissue diseases in the diagnostic groups (systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, mixed connective tissue disease, scleroderma, polymyositis/ dermatomyositis). In the healthy control group, there was a statistically significant difference between KL-6 levels in smokers and non-smokers. Smokers had significantly higher serum KL-6 levels compared with non-smokers (p < 0.05). There was no statistically significant difference between smoking status (pack-year) and serum KL-6 levels. There was no statistically significant correlation between serum KL-6 levels and time since diagnosis of CTD and CTD-ILD. The level of KL-6 as a predictive factor could be used to identify the clinical development of ILD before it is detected on imaging modality. Further prospective clinical studies are needed to define whether levels of KL-6 might have prognostic value or might predict progressive ILD.